[go: up one dir, main page]

MA32811B1 - Nouveaux composés - Google Patents

Nouveaux composés

Info

Publication number
MA32811B1
MA32811B1 MA33866A MA33866A MA32811B1 MA 32811 B1 MA32811 B1 MA 32811B1 MA 33866 A MA33866 A MA 33866A MA 33866 A MA33866 A MA 33866A MA 32811 B1 MA32811 B1 MA 32811B1
Authority
MA
Morocco
Prior art keywords
new compounds
compounds
relates
drug
excessive
Prior art date
Application number
MA33866A
Other languages
Arabic (ar)
English (en)
Inventor
Heinz Stadtmueller
Ioannis Sapountzis
Original Assignee
Boehringer Ingemheim Internat Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42115425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32811(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingemheim Internat Gmbh filed Critical Boehringer Ingemheim Internat Gmbh
Publication of MA32811B1 publication Critical patent/MA32811B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE DES COMPOSÉS DE LA FORMULE GÉNÉRALE (I) DANS LAQUELLE A, B, X, R1 À R3 SONT TELS QUE DÉFINIS DANS LA REVENDICATION 1, LESDITS COMPOSÉS ÉTANT APPROPRIÉS POUR LE TRAITEMENT DE MALADIES CARACTÉRISÉES PAR UNE PROLIFÉRATION CELLULAIRE EXCESSIVE OU ANORMALE. L'INVENTION CONCERNE ÉGALEMENT LEUR UTILISATION POUR PRÉPARER UN MÉDICAMENT AYANT LES PROPRIÉTÉS MENTIONNÉES CI-DESSUS.
MA33866A 2008-11-24 2011-05-20 Nouveaux composés MA32811B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08169807 2008-11-24
EP09169654 2009-09-07
PCT/EP2009/065768 WO2010058032A2 (fr) 2008-11-24 2009-11-24 Nouveaux composés

Publications (1)

Publication Number Publication Date
MA32811B1 true MA32811B1 (fr) 2011-11-01

Family

ID=42115425

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33866A MA32811B1 (fr) 2008-11-24 2011-05-20 Nouveaux composés

Country Status (26)

Country Link
US (4) US8846689B2 (fr)
EP (1) EP2367800B9 (fr)
JP (1) JP5622740B2 (fr)
KR (1) KR101710058B1 (fr)
CN (2) CN102292322B (fr)
AP (1) AP2960A (fr)
AR (1) AR074210A1 (fr)
AU (1) AU2009317170B2 (fr)
BR (1) BRPI0922801B1 (fr)
CA (1) CA2744351C (fr)
CL (1) CL2011001215A1 (fr)
CO (1) CO6511283A2 (fr)
EA (1) EA021997B1 (fr)
EC (1) ECSP11011079A (fr)
ES (1) ES2664499T3 (fr)
GE (1) GEP20146072B (fr)
IL (1) IL212814B (fr)
MA (1) MA32811B1 (fr)
MX (1) MX337116B (fr)
MY (1) MY176944A (fr)
NZ (1) NZ592925A (fr)
PE (1) PE20120034A1 (fr)
TN (1) TN2011000259A1 (fr)
TW (1) TWI491605B (fr)
UY (1) UY32259A (fr)
WO (1) WO2010058032A2 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201024281A (en) 2008-11-24 2010-07-01 Boehringer Ingelheim Int New compounds
TWI491605B (zh) 2008-11-24 2015-07-11 Boehringer Ingelheim Int 新穎化合物
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
US8729265B2 (en) 2009-08-14 2014-05-20 Boehringer Ingelheim International Gmbh Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
EP2675793B1 (fr) 2011-02-17 2018-08-08 Cancer Therapeutics Crc Pty Limited Inhibiteurs de fak
DK2675794T3 (da) 2011-02-17 2019-05-06 Cancer Therapeutics Crc Pty Ltd Selektive fak-inhibitorer
WO2013146963A1 (fr) * 2012-03-28 2013-10-03 武田薬品工業株式会社 Composé hétérocyclique
HUE052080T2 (hu) 2013-09-09 2021-04-28 Peloton Therapeutics Inc Ariléterek és azok felhasználásai
US10807948B2 (en) 2015-03-11 2020-10-20 Peloton Therapeutics, Inc. Aromatic compounds and uses thereof
WO2016145032A1 (fr) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Compositions utilisées pour traiter l'hypertension artérielle pulmonaire
US10155726B2 (en) 2015-03-11 2018-12-18 Peloton Therapeutics, Inc. Substituted pyridines and uses thereof
US10512626B2 (en) 2015-03-11 2019-12-24 Peloton Therapeautics, Inc. Compositions for use in treating glioblastoma
US10335388B2 (en) 2015-04-17 2019-07-02 Peloton Therapeutics, Inc. Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
US20170066778A1 (en) * 2015-09-04 2017-03-09 Aunova Medchem LLC Solubility for target compounds
US20230145356A1 (en) 2019-11-18 2023-05-11 Inxmed (Nanjing) Co., Ltd. Use of fak inhibitor in preparation of drug for treating tumors having nras mutation
EP4066837A4 (fr) * 2019-11-28 2023-12-06 Inxmed (Nanjing) Co., Ltd. Utilisation de bi853520 dans le traitement du cancer
US20230079055A1 (en) 2020-02-05 2023-03-16 Inxmed (Nanjing) Co., Ltd. Combination of bi853520 with chemotherapeutic drugs
TW202206425A (zh) * 2020-08-03 2022-02-16 大陸商應世生物科技（南京）有限公司 化合物的固體形式
TW202313044A (zh) 2021-08-16 2023-04-01 大陸商應世生物科技（南京）有限公司 Ｉｎ１００１８與ｐｌｄ的聯用
WO2023107705A1 (fr) 2021-12-10 2023-06-15 Incyte Corporation Amines bicycliques utilisées comme inhibiteurs de cdk12
CN118369120A (zh) 2021-12-10 2024-07-19 应世生物科技(南京)有限公司 治疗肿瘤的药物组合及用途
CA3238851A1 (fr) 2021-12-21 2023-06-29 Yuli Xie Compose utilise comme inhibiteur de fak et son utilisation
AU2023224815A1 (en) * 2022-02-28 2024-09-26 Wigen Biomedicine Technology (shanghai) Co., Ltd. Compound as fak inhibitor and use thereof
EP4545080A1 (fr) * 2022-06-24 2025-04-30 Inxmed (Nanjing) Co., Ltd. Combinaison pharmaceutique pour le traitement de tumeurs et son utilisation
CN117462553A (zh) * 2022-07-20 2024-01-30 益方生物科技(上海)股份有限公司 药物组合产品以及组合疗法
AU2023327858A1 (en) * 2022-08-24 2025-01-30 Inxmed (Nanjing) Co., Ltd. Pharmaceutical combination of fak inhibitor and microtubule inhibitor and use thereof
CN118580221A (zh) * 2023-03-02 2024-09-03 应世生物科技(南京)有限公司 化合物的固体形式

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
ATE342892T1 (de) 1998-08-29 2006-11-15 Astrazeneca Ab Pyrimidine verbindungen
US6906067B2 (en) * 1999-12-28 2005-06-14 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-α expression
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
CA2463989C (fr) 2001-10-17 2012-01-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Derives pyrimidine, compositions pharmaceutiques contenant ces composes, utilisation et procede de fabrication de ces composes
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
EA200500721A1 (ru) 2002-11-28 2005-12-29 Шеринг Акциенгезельшафт Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств
CL2004000303A1 (es) * 2003-02-20 2005-04-08 Tibotec Pharm Ltd Compuestos derivados de pirimidinas y triazinas; proceso de preparacion; composicion farmaceutica; y su uso para inhibir la replicacion del vih.
ATE433447T1 (de) 2003-02-20 2009-06-15 Smithkline Beecham Corp Pyrimiidinverbindungen
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
US7504396B2 (en) * 2003-06-24 2009-03-17 Amgen Inc. Substituted heterocyclic compounds and methods of use
PT1660458E (pt) 2003-08-15 2012-04-27 Novartis Ag 2,4-pirimidinodiaminas úteis no tratamento de doenças neoplásicas, desordens inflamatórias e do sistema imunitário
EP1598343A1 (fr) 2004-05-19 2005-11-23 Boehringer Ingelheim International GmbH Dérivés de 2-arylaminopyrimidines comme des inhibiteurs de PLK
US7521457B2 (en) * 2004-08-20 2009-04-21 Boehringer Ingelheim International Gmbh Pyrimidines as PLK inhibitors
GB0419160D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
KR20070057798A (ko) 2004-09-30 2007-06-07 티보텍 파마슈티칼즈 리미티드 Ｈｉｖ를 저해하는 5-탄소환 또는 복소환으로 치환된피리미딘
CN101103028A (zh) 2005-01-14 2008-01-09 神经能质公司 经杂芳基取代的喹啉-4-基氨类似物
US20070032514A1 (en) 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
WO2007035309A1 (fr) 2005-09-15 2007-03-29 Merck & Co., Inc. Inhibiteurs de la tyrosine kinase
US20080318989A1 (en) * 2005-12-19 2008-12-25 Burdick Daniel J Pyrimidine Kinase Inhibitors
FR2896503B1 (fr) * 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
TW200804364A (en) 2006-02-22 2008-01-16 Boehringer Ingelheim Int New compounds
UA95949C2 (ru) 2006-03-31 2011-09-26 Янссен Фармацевтика, Н.В. Бензоимидазол-2-илпиримидины и пиразины как модуляторы рецептора гистамина h4
GB0619343D0 (en) 2006-09-30 2006-11-08 Vernalis R&D Ltd New chemical compounds
WO2008040951A1 (fr) 2006-10-03 2008-04-10 Astrazeneca Ab Composés
ES2550152T3 (es) 2006-12-13 2015-11-04 F. Hoffmann-La Roche Ag Derivados de 2-(piperidin-4-il)-4-fenoxi-o fenilamino-pirimidina como inhibidores no nucleósidos de transcriptasa inversa
EP2099771A1 (fr) * 2006-12-19 2009-09-16 Genentech, Inc. Inhibiteurs de pyrimidine kinase
JP5539734B2 (ja) 2007-01-31 2014-07-02 ワイエム・バイオサイエンシズ・オーストラリア・ピーティーワイ・リミテッド チオピリミジンベースの化合物およびその使用
PT2154967E (pt) * 2007-04-16 2014-06-05 Hutchison Medipharma Entpr Ltd Derivados de pirimidina
CA2718858A1 (fr) 2008-03-20 2009-09-24 Boehringer Ingelheim International Gmbh Elaboration regioselective de pyrimidines substituees
RU2536584C2 (ru) 2008-06-27 2014-12-27 Авила Терапьютикс, Инк. Гетероарильные соединения и их применение
TWI491605B (zh) 2008-11-24 2015-07-11 Boehringer Ingelheim Int 新穎化合物
TW201024281A (en) 2008-11-24 2010-07-01 Boehringer Ingelheim Int New compounds
EP2440559B1 (fr) 2009-05-05 2018-01-10 Dana-Farber Cancer Institute, Inc. Inhibiteurs d'egfr et procédés de traitement de troubles

Also Published As

Publication number Publication date
JP2012509864A (ja) 2012-04-26
MX2011005420A (es) 2011-06-16
EA201100794A1 (ru) 2012-01-30
US20110288071A1 (en) 2011-11-24
CN102292322A (zh) 2011-12-21
ES2664499T3 (es) 2018-04-19
US20150376141A1 (en) 2015-12-31
US20160362404A1 (en) 2016-12-15
IL212814A0 (en) 2011-07-31
CA2744351C (fr) 2017-07-04
UY32259A (es) 2010-06-30
GEP20146072B (en) 2014-04-10
IL212814B (en) 2018-05-31
JP5622740B2 (ja) 2014-11-12
WO2010058032A2 (fr) 2010-05-27
CO6511283A2 (es) 2012-08-31
CN104478865B (zh) 2017-09-22
EA021997B1 (ru) 2015-10-30
BRPI0922801A2 (pt) 2020-08-04
AP2960A (en) 2014-08-31
BRPI0922801B1 (pt) 2021-12-21
MY176944A (en) 2020-08-27
CN104478865A (zh) 2015-04-01
US9676762B2 (en) 2017-06-13
TWI491605B (zh) 2015-07-11
US20140371205A1 (en) 2014-12-18
PE20120034A1 (es) 2012-02-19
ECSP11011079A (es) 2011-06-30
KR101710058B1 (ko) 2017-02-24
HK1160841A1 (zh) 2012-08-17
EP2367800B9 (fr) 2021-10-20
US8846689B2 (en) 2014-09-30
CN102292322B (zh) 2015-11-25
EP2367800B1 (fr) 2018-02-28
ES2664499T9 (es) 2022-01-03
AU2009317170A1 (en) 2010-05-27
TN2011000259A1 (en) 2012-12-17
KR20110084551A (ko) 2011-07-25
MX337116B (es) 2016-02-12
WO2010058032A3 (fr) 2010-07-15
AU2009317170B2 (en) 2015-05-28
AR074210A1 (es) 2010-12-29
EP2367800A2 (fr) 2011-09-28
TW201026682A (en) 2010-07-16
CA2744351A1 (fr) 2010-05-27
NZ592925A (en) 2013-04-26
AP2011005706A0 (en) 2011-06-30
CL2011001215A1 (es) 2011-09-30

Similar Documents

Publication Publication Date Title
MA32811B1 (fr) Nouveaux composés
MA32505B1 (fr) 5-alcynyl-pyrimidines
EA201170521A1 (ru) Новые соединения
ECSP078060A (es) 2,4-diamino-pirimidinas como inhibidores de aurora
EA201001639A1 (ru) Композиции и способы их получения и применения
CY1118129T1 (el) 5-αλκυνυλ-πυριμιδινες
MA33937B1 (fr) Composes pyrazole comme antagonistes du recepteur crth2
ATE522536T1 (de) Pyrrolopyrazin-kinasehemmer
MX2013004491A (es) Boronatos como inhibidores de arginasa.
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
EA201070422A1 (ru) Производные оксадиазола
GEP20146125B (en) Aminopyrimidines as syk inhibitors
EA200870514A1 (ru) Ацетиленовые гетероарильные соединения
ATE517107T1 (de) Pyrrolopyrazinkinaseinhibitoren
PH12013500152A1 (en) New aminopyrazoloquinazolines
MX2012002641A (es) Inhibidores de cinasa janus (jak).
ATE554066T1 (de) Entzündungshemmende substituierte cyclobutendionverbindungen
UA107183C2 (uk) Феніламіно-ізонікотинамідні сполуки, їх застосування, фармацевтична композиція, що їх містить, та спосіб лікування гіперпроліферативних захворювань
GEP20135959B (en) Aryl piperazine and their usage as alpha2c antagonists
EA201170344A1 (ru) Азаиндольные ингибиторы iap
IN2012DN03846A (fr)
MA32945B1 (fr) Tétrahydropyrane spiro pyrrolidinone et pipéridinone substituées, leur préparation et leur utilisation thérapeutique
MX2010009837A (es) Tiazolil-dihidro-indazoles.
UA110332C2 (en) Use of 2,3-dihydroxypropyldodecanoate for treatment of seborrhea
DE602006009789D1 (de) Acetylenderivate